One-day Treatment of Small Molecule 8-Bromo-cyclic AMP Analogue Induces Cell-based VEGF production for In Vitro Angiogenesis and Osteoblastic Differentiation by Lo, Kevin W.-H. et al.
University of Connecticut
OpenCommons@UConn
UCHC Articles - Research University of Connecticut Health Center Research
11-2013
One-day Treatment of Small Molecule 8-Bromo-
cyclic AMP Analogue Induces Cell-based VEGF
production for In Vitro Angiogenesis and
Osteoblastic Differentiation
Kevin W.-H. Lo
University of Connecticut School of Medicine and Dentistry
Ho Man Kan
University of Connecticut School of Medicine and Dentistry
Keith A. Gagnon
University of Connecticut School of Medicine and Dentistry
Cato T. Laurencin
University of Connecticut School of Medicine and Dentistry
Follow this and additional works at: https://opencommons.uconn.edu/uchcres_articles
Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons
Recommended Citation
Lo, Kevin W.-H.; Kan, Ho Man; Gagnon, Keith A.; and Laurencin, Cato T., "One-day Treatment of Small Molecule 8-Bromo-cyclic
AMP Analogue Induces Cell-based VEGF production for In Vitro Angiogenesis and Osteoblastic Differentiation" (2013). UCHC
Articles - Research. 276.
https://opencommons.uconn.edu/uchcres_articles/276
One-day Treatment of Small Molecule 8-Bromo-cyclic AMP 
Analogue Induces Cell-based VEGF production for In Vitro 
Angiogenesis and Osteoblastic Differentiation
Kevin W.-H. Lo1,2,3,4,*, Ho Man Kan1,2,5, Keith A. Gagnon1, and Cato T. Laurencin1,2,4,5,6,*
1Institute for Regenerative Engineering, University of Connecticut Health Center, School of 
Medicine, Farmington, CT 06030
2The Raymond and Beverly Sackler Center for Biomedical, Biological, Physical and Engineering 
Sciences, University of Connecticut Health Center, School of Medicine, Farmington, CT 06030
3Department of Medicine, Division of Endocrinology, University of Connecticut Health Center, 
School of Medicine, Farmington, CT 06030
4Department of Biomedical Engineering, University of Connecticut, School of Engineering, Storrs, 
CT 06268
5Department of Orthopaedic Surgery, University of Connecticut Health Center, School of 
Medicine, Farmington, CT 06030
6Department of Chemical, Materials and Biomolecular Engineering, University of Connecticut, 
School of Engineering, Storrs, CT 06268
Abstract
Small molecule based regenerative engineering is emerging as a promising strategy for 
regenerating bone tissue. Small molecule cAMP analogues have been proposed as novel biofactors 
for bone repair and regeneration, and while promising, the effect that these small molecules have 
on angiogenesis, a critical requirement for successful bone regeneration, is still unclear. Our 
previous research demonstrated that the small molecule cAMP analogue 8-bromoadenosine-3’,5’-
cyclic monophosphate (8-Br-cAMP) was able to promote initial osteoblast adhesion on a 
polymeric scaffold via cAMP signaling cascades. Here, we report that 8-Br-cAMP is capable of 
inducing in vitro cell-based VEGF production for angiogenesis promotion. We first demonstrated 
that treating osteoblast-like MC3T3-E1 cells with 8-Br-cAMP for one day significantly increased 
VEGF production and secretion. We then demonstrated that 8-Br-cAMP induced cell-secreted 
VEGF is biologically active and may promote angiogenesis as evidenced by increased endothelial 
cells (HUVECs) migration and tubule formation. In addition, treatment of MC3T3-E1 cells with 
8-Br-cAMP for as short as a single day resulted in enhanced ALP activity as well as matrix 
mineralization, demonstrating in vitro osteoblastic differentiation. A short term 8-Br-cAMP 
treatment also addresses the concern of non-specific cytotoxicity, as our data indicate that a one-
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day 8-Br-cAMP treatment scheme supports cellular proliferation of MC3T3-E1 cells as well as 
HUVECs. While the major concern associated with small molecule drugs is the risk of non-
specific cytotoxicity, the short exposure treatment outlined in this paper provides a very promising 
strategy to mitigate the risk associated with small molecules.
Keywords
angiogenesis; osteoblastic differentiation; regenerative engineering; bone regeneration; small 
molecules; cAMP; morphogenesis
Introduction
Regenerative engineering technologies using bioactive molecules, stem cells, and advanced 
biomaterials have been proposed as promising approaches for bone repair and regeneration 
(Laurencin and Khan, 2012; Ozdemir et al., 2013). Foremost, the delivery and evaluation of 
a variety of bioactive molecules have been widely researched (Cui et al., 2013). One such 
bioactive molecule, bone morphogenetic proteins (BMPs), have shown great potential for 
use in bone regeneration and repair (Bessa et al., 2008; Lo et al., 2012d). While these 
proteinaceous growth factors have been shown to facilitate bone formation within tissue 
engineered scaffolds, the resulting neotissue is often found only at the surface of the scaffold 
and not within the scaffold interior due to poor vascularization and limited oxygen supply 
(Kim et al., 2012; Tischer et al., 2010). To enhance vascularization, recombinant angiogenic 
factors such as vascular endothelial growth factor (VEGF) have been extensively researched 
as cofactors to be delivered in scaffolds (Chiu et al., 2011; Cui et al., 2013; Ennett et al., 
2006). It should be noted that while the identification and production of recombinant protein 
growth factors that play key roles in bone repair and regeneration have generated much 
enthusiasm and numerous clinical trials, the outcomes of many of these clinical trials have 
been disappointing (Lee et al., 2010; Lo et al., 2012d). In general, the ability to regenerate 
functional tissues from recombinant protein growth factors have been hindered by a number 
of limitations, including high manufacturing cost, contamination, and unwanted immune 
responses (Lo et al., 2012a; Lo et al., 2011a). Therefore, an alternative form of biofactors is 
needed to diminish these drawbacks. Small molecules that carry the capacity to induce bone 
regeneration have recently gained more spotlight in the field because they possess intrinsic 
physical properties (e.g. non-immuogenic, chemically stable) that allow them to overcome 
the issues observed with recombinant protein growth factors (Doorn et al., 2013; Egusa et 
al., 2010; Lo et al., 2012a; Lo et al., 2011a; Masuya and Teno, 2010; Sefcik et al., 2008; 
Segar et al., 2013). We have previously demonstrated that the small molecule 6-Bnz-cAMP, 
a target-specific cAMP-analog that interacts via the protein kinase A (PKA) signaling 
pathway, was able to induce initial cell adhesion, differentiation, and mineralization of early 
passage osteoblast-like MC3T3-E1 cells on biodegradable polymeric scaffolds (Lo et al., 
2012b; Lo et al., 2011b). Similarly, it has been shown that other cAMP analogues have 
effects on regulating osteoblastic differentiation and mineralization in vitro and in vivo 
(Doorn et al., 2012a; Siddappa et al., 2008). cAMP is found ubiquitously in mammalian 
cells and acts as a common secondary messenger controlling diverse cellular processes 
including cell differentiation and morphogenesis (Beavo and Brunton, 2002). For instance, 
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in mouse and chick limb buds, a transient increase in intracellular cAMP levels during the 
onset of chondrogenesis has been observed (Ho et al., 1982; Solursh et al., 1979), suggesting 
that cAMP plays an important role in regulating this process. Similarly, dibutyryl cAMP 
analogue has been shown to enhance cartilage differentiation in the limb-bud mesoderm in 
both cell and organ cultures (Kosher and Savage, 1980), suggesting that cAMP plays a 
crucial role in complex tissue regeneration.
Although the effect of cAMP analogues on angiogenesis is unclear, cAMP mediated 
signaling pathways have been implicated in angiogenesis regulation through increased 
VEGF expression (Namkoong et al., 2009). This observation has prompted us to test 
whether various cAMP analogues can induce in vitro angiogenesis by increasing VEGF 
production. In this report, we investigated the effects of various cAMP analogues (8-Br-
cAMP, 6-Bnz-cAMP, and 8-CPT-2Me-cAMP) on VEGF production using MC3T3-E1 
osteoblast-like cells. As illustrated in figure 1A, 8-Br-cAMP is an activator of PKA and the 
exchange protein activated by cyclic AMP (Epac) whereas 6-Bnz-cAMP and 8-CPT-2Me-
cAMP exclusively target PKA and Epac, respectively. These cAMP analogues have been 
well established as tools for studying various cAMP mediated signal transduction in a wide 
range of cellular processes (Christensen et al., 2003; Lo et al., 2011b; Schwede et al., 2000). 
The hypothesis of our investigation was that the 8-Br-cAMP small molecule plays a highly 
important role in bone regeneration for bone regenerative engineering.
Methods
Reagents
N6-benzoyladenosine-3’,5’-cyclic monophosphate (6-Bnz-cAMP), 8-bromoadenosine-3’,5’-
cyclic monophosphate (8-Br-cAMP), and 8-(4-Chlorophenylthio)-2’-O-methyladenosine-3’,
5’-cyclic monophosphate (8-CPT-2Me-cAMP) were purchased from Alexis Biochemicals 
(San Diego, CA); Fibronectin was purchased from Gibco (Grand Island, NY).
Cell Culture
All cells were maintained at 37°C in a 5% CO2-humidified incubator. MC3T3-E1 
osteoblast-like cells (American Type Culture Collection, Manassas, VA) (passage number 
21 to 30) were used to study VEGF synthesis in response to cAMP treatment and in vitro 
osteoblastic differentiation and proliferation. The cells were maintained in regular growth 
medium containing alpha minimal essential medium (α–MEM) (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin G, and 100 mg/mL 
streptomycin. Cells cultured in osteogenic medium (alpha minimal essential medium 
supplemented with 10% FBS, 1% of antibiotic, 3 mM β-glycerolphosphate, and 10 μg/ml 
ascorbic acid) served as a positive control for osteoblastic differentiation. HUVECs, 
purchased from Lonza (Basel, Switzerland) (passage number 3 to 8) were used for in vitro 
angiogenesis studies. Cells were grown in endothelial cell growth medium 2 (EGM2) 
(Lonza, Basel, Switzerland) supplemented with 10% FBS and 1% of antibiotic (100U/ml 
penicillin G and 100mg/ml streptomycin).
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Cell Proliferation Assay
Cell proliferation studies were performed using a non-radioactive cell proliferation assay kit 
(MTS) (Promega, Madison, WI) which was performed according to the manufacturer's 
instructions. Cells were collected at days 1, 3, and 7 for the proliferation assays. For one-day 
treatment, 100 μM of 8-Br-cAMP was added to the medium at the time of cell seeding. 100 
μM of 8-Br-cAMP was found to be an optimal concentration to induce MC3T3-E1 cell 
adhesion (Lo et al., 2011b). About 24 h post-seeding, the medium was replaced with fresh 
medium without 8-Br-cAMP supplementation. For continuous 8-Br-cAMP treatment, 100 
μM of 8-Br-cAMP was added to the medium at the time of cell seeding. The medium 
supplemented with 8-Br-cAMP was replaced every 3 to 4 days.
Cell Viability Assay
Viabilities of MC3T3-E1 and HUVEC cells on day 1, 3 and 7 with or without one-day 8Br-
cAMP treatment were measured by the live/dead viability kit (Life Technologies, Grand 
Island, NY). Cells were stained with calcein AM for live cells (green) and ethidium 
homodimer for dead cells (red). The stained cells were then counted using confocal 
microscopy (Zeiss, USA). Experiments were performed in triplicate. Three regions were 
randomly selected and analyzed for each experiment.
Enzyme-Linked Immunosorbent Assay (ELISA)
A mouse Quantikine intact VEGF ELISA kit (R&D Systems, Minneapolis, MN) was used to 
quantify cell-secreted VEGF according to the manufacturer's instructions. The assay product 
solution was visualized using a Biotek Synergy™ HT microplate reader (Winooski, VT) at a 
wavelength of 450 nm. The absorbance was converted to VEGF concentration with the use 
of a kit provided mouse VEGF standard (0 – 500 pg/mL).
Conditioned media preparation
Conditioned media were prepared because we wanted to investigate the trophic effect of the 
cAMP treated cells. Briefly, osteoblast-like MC3T3-E1 cells (1 million) were plated in 10-
cm tissue culture plates in regular growth medium with or without 100 μM 8-Br-cAMP 
supplement. After 1 day of incubation, media were collected and directly applied to 
HUVECs for in vitro angiogenesis analysis. Medium collected from the 8-Br-cAMP treated 
cells was designated as “8-Br-cAMP conditioned medium” and medium collected from the 
untreated control cells was designated as “Control conditioned medium”.
Real-time reverse transcription PCR analysis
HUVEC were plated and grown to 90% confluence in 10 cm2 plate. They were then treated 
with corresponding conditioned media for 3 hours. Quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) was used to assess the angiogenesis markers Vegfa, 
Icam1, and Vcam1 gene expressions. Total RNA was isolated using the RNeasy Mini 
System (Qiagen, Hilden, Germany) according to the manufacturer's instructions. 1μg total 
RNA was used as a template for RNA to cDNAEcoDry Premix System (Clontech) to 
synthesis complementary DNA (cDNA). A Light cycler instrument (Bio-Rad iCycler iQ 
system) was used to perform real time PCR using SuperMix Premix (Biorad) and Taqman 
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Gene Expression Assays (Applied Biosystems, Guilford, CT). ΔΔCt method is used to 
calculate the relative fold expression of the genes of interest by normalized to a 
housekeeping gene, GAPDH, and untreated control.
In vitro capillary network formation assay
Matrigel (270 μL) (BD Biosciences, San Jose, CA) was added to each well of a 24-well 
culture plate according to the manufacturer's instruction. After the gel solidified, 40,000 
HUVECs in 1 ml of corresponding medium were added to the well. The cells were 
incubated at 37 °C and 5% CO2 for 10-12 h (He et al., 2013). The formation of the capillary/
tube-like networks were examined using a light microscope (Olympus, USA). Five random 
fields for each sample were taken at 4X magnification. ImageJ software (NIH) was used to 
quantify the total length of capillary tubes. A tubule was defined as a capillary structure with 
a length at least 4 times the width of individual well-separated cells (Chen et al., 2004; 
Wieghaus et al., 2006). Assays were performed in triplicate.
Endothelial cell transwell migration assay
The migration activity of HUVEC was assayed using a Boyden Chamber assay method. 
50,000 HUVEC cells in serum-free starvation EBM-2 medium were placed into 24-well 
sized Transwell (Corning, New York, NY) which were pre-coated with 10 μg/ml 
fibronectin. Corresponding conditioned media were added to the lower chamber. The plate 
was incubated at 37 °C with 5% CO2 for 10-12 h. The cells that remained on the upper 
surface of the filter membrane were rinsed with PBS and removed by cotton swab. The 
migrated cells that located on the lower surface of the filter membrane were fixed in 100% 
cold methanol for 15 min. The membranes were then cut off, stained with 50 μg/ml DAPI 
(Sigma-Aldrich, St Louis, MO) for 10 min, and mounted to cover slides. The migrated cells 
were quantified under a confocal microscope (Zeiss, USA). Assays were performed in 
triplicate.
Alkaline phosphatase activity (ALP) assay
To investigate the osteogenic effect of one-day treatment of 8-Br-cAMP on osteoblastic 
differentiation, we first measured the ALP activity since this is one of the most important 
early markers for osteoblastic differentiation (Katagiri et al., 1994). MC3T3-E1 Cells were 
cultured with regular growth medium with either short or continuous 8-Br-cAMP treatments 
at a concentration of 100 μM. ALP activity was measured at 7 days in culture. ALP activity 
was measured using an alkaline phosphatase substrate assay kit according to the 
manufacturers’ instructions (Bio-Rad, Hercules, CA). For one-day 8-Br-cAMP treatment, 
100 μM 8-Br-cAMP was added to the medium at the time of cell seeding. About 24 h after 
incubation, the medium was replaced with fresh medium without 8-Br-cAMP supplement. 
For continuous 8-Br-cAMP treatment, 100 μM 8-Br-cAMP was added to the medium at the 
time of cell seeding. The medium supplemented with 8-Br-cAMP was replaced every 3 to 4 
days. At day 7, media were removed and cells were washed 3-4 times with PBS. The 
washed cells were lysed with 1% Triton X-100 at room temperature for 5 min. ALP 
substrate solution was added to the cell lysate at 37 °C for 1-2 h. The assay product solution 
was visualized using a Biotek Synergy™ HT microplate reader (Winooski, VT) at a 
wavelength of 405 nm. The absorbances were normalized to cellular DNA. Cellular DNA 
Lo et al. Page 5
J Tissue Eng Regen Med. Author manuscript; available in PMC 2015 July 09.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
measurements were performed using PicoGreen dsDNA assay kit (Molecular Probes, 
Eugene, OR) according to the manufacturers’ procedures.
Matrix mineralization assay
After day 21 of culture in osteogenic medium, the mineralized matrix of the cultured 
osteoblasts was quantified by colorimetric determination of total calcium deposited in the 
matrix (Calcium Liquicolor, Stanbio Laboratory, Boerne, TX). This procedure was 
performed as previously described (Lo et al., 2012c).
Statistical Analysis
Statistical analysis was performed on samples using the Student's t-test (Microsoft Excel). 
The experiments were performed in at least triplicate and the level of significance was set at 
p < 0.05. An asterisk (*) in the figures denotes significance between groups.
Results
Effect of various cAMP analogues on VEGF synthesis in osteoblast-like MC3T3-E1 cells
To investigate the role of cAMP analogues on VEGF production in MC3T3-E1 cells, we 
employed several different cAMP analogues (figure 1A). As shown in figure 1B, the ELISA 
data revealed that 100 μM 8-Br-cAMP significantly promoted VEGF secretion by MC3T3-
E1 cells after one day of incubation when compared to untreated control cells. There were 
no statistically significant differences in 6-Bnz-cAMP and 8-CPT-2Me-cAMP treated cells 
compared to the untreated control cells.
Effect of conditioned media on the angiogenic behavior of endothelial cells in vitro
Since VEGF has been demonstrated to have angiogenic effects on endothelial cells, the 
angiogenic activities of the secreted VEGF in conditioned media was firstly investigated by 
examining its influence on various angiogenic markers expression in endothelial cells. We 
examined the effects of conditioned media on Vascular Endothelial Growth Factor A 
(VEGF-A), Intercellular Adhesion Molecule 1 (ICAM-1), and Vascular Cell Adhesion 
Protein 1 (VCAM-1) mRNA levels in HUVECs that had been cultured in conditioned media 
for 3h. Figure 1C reveals that HUVECs cultured in 8-Br-cAMP conditioned medium 
resulted in a significant increase in VEGF-A, ICAM-1, and VCAM-1 mRNA levels.
During angiogenesis, endothelial cell migration plays an essential role in vascular budding 
(Lamalice et al., 2007; Osusky et al., 2004). To test the effects of the conditioned media on 
endothelial cell migration, conditioned media from treated or untreated MC3T3-E1 cells was 
directly added to HUVECs in Boyden Chambers and endothelial cell migration activity was 
analyzed. Figure 2A revealed that increased cell migration was observed when HUVECs 
were supplemented with 8-Br-cAMP exposed MC3T3-E1 cell conditioned medium. In 
contrast, conditioned medium from control untreated cells lacked this activity (Figure 2B). 
The numbers of migrated cells were quantitated in each experimental group (Figure 2C).
It is generally believed that the ability of endothelial cells to form capillary tube network is 
an important prerequisite for subsequent angiogenesis (Folkman and Haudenschild, 1980; 
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Osusky et al., 2004). To test the ability of secreted VEGF to induce capillary tube formation, 
conditioned media from osteoblast-like MC3T3-E1 cells was directly added to HUVECs and 
capillary network formation was determined. An endothelial tube was defined as a 
multicellular structure with a length at least 4 times its width (Sun et al., 2004; Wieghaus et 
al., 2006). HUVECs were cultured in Matrigel with conditioned media for 10-12 h. Figure 
3A revealed that HUVECs supplemented with 8-Br-cAMP conditioned medium displayed 
more capillary tube like structures than the control sample as shown in Figure 3B. These 
observations were quantified using ImageJ software (NIH) to determine the length of the 
tube-like structures (Figure 3C). Taken together, the observations from Figures 2 and 3 
indicated that the 8-Br-cAMP conditioned medium significantly enhanced migration and 
capillary formation in vitro.
Effect of one-day treatment of 8-Br-cAMP on osteoblastic differentiation
We next tested the effect of the one-day 8-Br-cAMP treatment on osteogenic differentiation 
of MC3T3-E1 cells. As shown in Figure 4A, one-day 8-Br-cAMP treatment showed 
significant increases in ALP activities when compared to the untreated control group at day 
7. These observations indicated that treatment of cells with 8-Br-cAMP for one day was able 
to induce osteoblastic differentiation in vitro. Matrix mineralization is a late stage marker of 
osteoblastic differentiation. As shown in figure 4B, MC3T3-E1 cells exposed to one-day 8-
Br-cAMP treatment scheme exhibited a significant increase in calcium level as compared to 
cells cultured in osteogenic medium alone.
Effect of small molecule 8-Br-cAMP on cellular proliferation and cell viability
The effects of 8-Br-cAMP treatment on MC3T3-E1 and HUVEC proliferation were assessed 
next. Both MC3T3-E1 and HUVECs were cultured in regular growth medium with either 
one-day or continuous 8-Br-cAMP treatments at a concentration of 100 μM. Cellular 
proliferation was evaluated over a period of 7 days of culture using a cell proliferation assay 
kit (MTS assay kit). The MTS assay is a routinely used method for accessing in vitro 
cytotoxicity of a chemical (Malich et al., 1997). Untreated cells were used as a control. The 
absorbance in the figure serves as a surrogate for the number of living cells in culture 
because a linear correlation between the absorbance (490 nm) and cell number was observed 
(data not shown). As shown in Figures 5A and 5B, there were no significant differences in 
cellular proliferation at day 1 among cells treated with 8-Br-cAMP when compared to the 
untreated control group for both MC3T3-E1 cells and HUVECs. These observations 
indicated that cell viability was maintained in 8-Br-cAMP treated cells during the early 
proliferative phase of both cell types. This data also suggested that one-day 8-Br-cAMP 
treatment does not induce direct cytotoxicity to the MC3T3-E1 cells and HUVECs at the 
concentration used in this study. At day 3, one-day 8-Br-cAMP did not significantly change 
the proliferation in MC3T3-E1 cells and HUVECs. However, continuous 8-Br-cAMP 
treatment significantly inhibited the proliferation of MC3T3-E1 cells when compared to the 
untreated control cells. At day 7, there was a significant decrease in cell proliferation for 
both cell types when treated with 8-Br-cAMP continuously. These results were consistent 
with the literature that has shown the anti-proliferative effects of treating cells with 8-Br-
cAMP (Doorn et al., 2012b; Lamb and Steinberg, 2002; Southgate and Newby, 1990; 
Starzec et al., 1994). Interestingly, there were no statistically significant differences in 
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cellular proliferation between one-day 8-Br-cAMP treated cells and untreated control cells 
during the entire period of assay. This data indicates that one-day 8-Br-cAMP treatment is 
much less cytotoxic than continuous 8-Br-cAMP treatment. To confirm that the low cell 
cytotoxicity for the one-day 8Br-cAMP treatment scheme, we performed cell viability assay 
to access the viability of cells for the one-day 8-Br-cAMP treatment. Figure 5C and D 
demonstrate that both 8-Br-cAMP treated and untreated control groups maintained >80% of 
the cell viability throughout the entire study period. In addition, there were no significant 
differences in cell viability among the cells treated with 8-Br-cAMP for 1 day when 
compared to the untreated control group at any time point. Taken together, these 
observations demonstrated that one-day 8-Br-cAMP treatment does not induce cell 
cytotoxicity in either MC3T3-E1 or HUVEC cells.
Discussion
Small molecules biofactors are low molecular weight organic compounds with medicinal 
properties. Due to characteristics inherent to small molecules, small molecule mediated-
bone regeneration is emerging as a promising strategy since it minimizes the limitations 
observed in protein-based therapeutics (Egusa et al., 2010; Lo et al., 2012a; Lo et al., 2011a; 
Sefcik et al., 2008). However, the major concern associated with small molecule 
therapeutics is their non-specific side effects (Lo et al., 2012a; Lo et al., 2011a). Due to their 
small molecular size, small molecules can easily penetrate through the cell membrane in 
non-target cells and perturb a number of metabolic and signaling pathways, eliciting 
unwanted physiological responses, i.e. side effects (Brouwers et al., 2011). Minimizing side 
effects from small molecules by reducing the frequency of their administration is a 
promising alternative strategy (Lo et al., 2013).
A number of small molecules have been shown to induce bone regeneration in vitro and in 
vivo (Egusa et al., 2010; Lo et al., 2012a), therefore, we chose to focus our study on the 
small molecule 8-Br-cAMP analogue because our present study demonstrates that medium 
collected from one-day 8-Br-cAMP treatment enhanced HUVECs’ migration and capillary 
formation, both of which are relevant events for in vitro angiogenesis. In addition, treatment 
of osteoblast-like MC3T3-E1 cells with 8-Br-cAMP for as short as one-day resulted in 
significant osteoblastic differentiation, shown by the enhanced ALP activity and matrix 
mineralization. To our knowledge, this is the first observation that a single dose cAMP 
analogue exposure for one day can lead to enhanced endothelial cell migration and capillary 
formation as well as osteoblastic differentiation. More importantly, the cell proliferation data 
indicated that a relatively short oneday 8-Br-cAMP treatment did not interfere with 
proliferation, whereas continuous 8-Br-cAMP treatment (3 or 7 days) significantly inhibited 
cellular proliferation (Figure 4). These findings may also provide a broader strategy for how 
to mitigate cytotoxicity risks associated with small molecules. One methodology for 
implementing transient small molecular exposure for tissue engineering would be to utilize 
relatively short ex vivo treatments of co-cultured osteoprogenitor cells and endothelial cells 
seeded on an osteoinductive scaffold with 8-Br-cAMP, followed by surgical implantation. 
While the results are promising, the activity of 8-Br-cAMP reported here was studied in the 
in vitro mouse cell model. Prior to preclinical animal studies, further in vitro cell study is 
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needed to investigate the differing in physiological effect of 8-Br-cAMP on mice and 
humans in terms of angiogenic activity, osteogenic activity, dosages, and treatment schemes.
The data presented provides a clear connection between cAMP signaling and VEGF 
expression in osteoblast-like MC3T3-E1 cells. Given that we and others have previously 
shown that 8-Br-cAMP triggers both PKA- and Epac-signaling cascades (Lo et al., 2011b; 
Rangarajan et al., 2003), our results also suggest that both PKA- and Epac-signaling 
cascades are associated with the extracellular production of VEGF in osteoblast-like 
MC3T3-E1 cells. This hypothesis was further supported by the fact that neither Epac 
specific activation (8-CPT-2Me-cAMP) nor PKA specific activation (6-Bnz-cAMP) 
significantly enhanced VEGF expression (Figure 1B). Consistent with our observations, 
Namkoong et al. demonstrated that forskolin, a cAMP rising agent, induced VEGF 
expression via the coordinated cross-talk between Epac- and PKA-mediated signaling in 
endothelial cells (Namkoong et al., 2009). The data also indicates that short-term treatment 
of MC3T3-E1 cells with 8-Br-cAMP triggered osteoblastic differentiation as demonstrated 
by enhanced ALP activity as well as matrix mineralization. It is worth noting that integrin-
dependent cell adhesion is responsible for osteoblast function since various integrin subunits 
have been shown to trigger different signaling which result in activation of distinct 
downstream signaling pathways (Giancotti and Ruoslahti, 1999; Lo et al., 2012c). 
Consistent with these observations, we have previously demonstrated that the small 
molecule 8-Br-cAMP can promote osteoblast cell adhesion, which is mediated by integrin 
subunits (Lo et al., 2011b). Taken together, these observations imply that the osteoblastic 
differentiation of MC3T3-E1 cells observed in this study may be partially due to the 
increased integrin-dependent cell adhesion induced by 8-Br-cAMP. Nevertheless, future 
experiments are needed to investigate the detailed molecular mechanisms underlying the 
osteogenic effects from one-day treatment of 8-Br-cAMP.
In this study, it was shown that (1) one-day 8-Br-cAMP treatment does not induce cell 
cytotoxicity, (2) one-day treatment of 8-Br-cAMP is adequate to induce differentiation of 
osteoblast-like MC3T3-E1 cells, and (3) medium collected from the one-day 8-Br-cAMP 
treated cells is adequate to promote migration and capillary formation of HUVECs due to 
the presence of VEGF. The data presented here provide a necessary prerequisite for the use 
of the small molecule 8-Br-cAMP for future in vitro and in vivo bone regenerative 
engineering studies.
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Figure 1. 
Effect of various cAMP analogues on extracellular VEGF production in osteoblast-like 
MC3T3-E1 cells. (A) Schematic representation of various cAMP analogues (8-Br-cAMP, 8-
CPT-2Me-cAMP, and 6-Bnz-cAMP) and their signaling pathways targets. (B) The cultured 
cells were stimulated by 100 μM 8-Br-cAMP, 100 μM 6-Bnz-cAMP, or 100 μM 8-
CPT-2Me-cAMP for 24 hours. Untreated cells were used as a control. Media were collected 
and analyzed by ELISA. Note that only 8-Br-cAMP treatment significantly enhanced 
secretion of VEGF in osteoblast-like MC3T3-E1 cells. Error bars represent means ± SD (n= 
4). (C) VEGF-A, ICAM-1, and VCAM-1 mRNA levels in HUVECs were determined after 
the cells were cultures in the conditioned media for 3h. Note: Control: control conditioned 
medium; 8-Br: 8-Br-cAMP conditioned medium. To facilitate the comparison of different 
experimental settings, cells cultured in “8-Br” condition were normalized to the cells treated 
with the control conditioned medium. Error bars represent means ± SD (n= 3).
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Figure 2. 
Effect of conditioned media on endothelial cell migration in the Boyden Chamber assay. 
HUVECs cultured in fibronectin-coated Boyden Chamber with (A) control conditioned 
medium or (B) 8-Br-cAMP conditioned medium. (C) Quantitation of HUVECs migration in 
each experimental group. These results indicate that the 8-Br-cAMP conditioned medium 
increases HUVECs migration. To facilitate the comparison of different experimental 
settings, migrated cells were normalized to the cells treated with the control conditioned 
medium. Error bars represent means ± SD (n= 4).
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Figure 3. 
Effect of conditioned media on capillary network formation in vitro. Light micrographs of 
HUVECs cultured in matrigel with (A) control conditioned medium or (B) 8-Br-cAMP 
conditioned medium. Scale bars are 200 μM. (C) Quantization of capillary network 
formation in each sample. These results indicate that the 8-Br-cAMP conditioned medium 
enhances capillary network formation. The range of the length of tube structures formed in 
the martigel assay is from ~60 μM to ~722 μM. To facilitate the comparison of different 
experimental settings, length of tubes were normalized to the length of tubes of the cells 
treated with the control conditioned medium. Error bars represent means ± SD (n= 6).
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Figure 4. 
Effect of various 8-Br-cAMP treatments on osteoblastic differentiation of osteoblast-like 
MC3T3-E1 cells. (A) ALP activities at day 7 were assessed by a commercial ALP activity 
substrate assay kit. Absorbance values were normalized to cellular DNA. To facilitate the 
comparison of different experimental settings, ALP activities were further normalized to the 
ALP activity of the cells exposed to the untreated control. Cell exposed to osteogenic 
medium served as a positive control experiment. #p<0.05 compared to “Control”, i.e. cells 
cultured in regular growth medium. (B) Effect of one-day 8-Br-cAMP treatment on matrix 
mineralization of MC3T3-E1 cells. Note that calcium level was significantly increased in 
cells when they were cultured in osteogenic medium with one-day 8-Br-cAMP treatment. To 
facilitate the comparison of different experimental settings, the value was normalized to 
cells exposed to the osteogenic medium. Error bars represent means ± SD (n= 3).
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Figure 5. 
Effects of various 8-Br-cAMP treatment schemes (one-day treatment versus continuous 
treatment) on cellular proliferations and viability in osteoblast-like MC3T3-E1 cells and 
HUVECs. Cellular proliferation of (A) MC3T3-E1 cells and (B) HUVECs in the presence of 
the small molecule 8-Br-cAMP (100 μM) was measured at days 1, 3, and 7 using a 
commercial cell proliferation assay kit (MTS). Cell viability was assessed in order to 
confirm the low cell cytotoxicity of one day 8-Br-cAMP treatment. Cell viability of (C) 
MC3T3-E1 cells and (D) and HUVECs in the presence of the small molecule 8-Br-cAMP 
(100 μM) for 1 day was measured at days 1, 3, and 7. Note: “One-day 8Br” for one-day 8-
Br-cAMP treatment and “Con’t 8Br” for continuous 8-Br-cAMP treatment. Error bars 
represent means ± SD (n= 3).
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